Goodrx Holdings Inc (GDRX)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $1.21B
Last updated: Nov 17, 2026 at 11:05 AM ET
Goodrx Holdings Inc (GDRX) Financials: Revenue, Profit and Cash Flow
Goodrx Holdings reported revenue of $796.85M for the fiscal year ended Dec 31, 2025, up 0.6% from the year before. That year, net income was $30.44M with a net margin of 3.8%, operating cash flow was $167.90M and free cash flow was $93.88M. The quarter ended Jun 30, 2026 had revenue of $200.41M and net income of $8.54M.
Revenue and Margins
The operating margin was 11.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $99.38M, a compound annual rate of 26.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $796.85M | +0.6% | 92.8% | 11.0% | 3.8% |
| Dec 2024 | $792.32M | +5.6% | 93.9% | 8.3% | 2.1% |
| Dec 2023 | $750.26M | -2.1% | 91.1% | -3.6% | -1.2% |
| Dec 2022 | $766.55M | +2.8% | 91.5% | 0.2% | -4.3% |
| Dec 2021 | $745.42M | +35.4% | 93.7% | 1.8% | -3.4% |
| Dec 2020 | $550.70M | +41.9% | 94.6% | -50.1% | -53.3% |
| Dec 2019 | $388.22M | +55.6% | 96.4% | 36.0% | 19.5% |
| Dec 2018 | $249.52M | +58.7% | 97.6% | 31.0% | 17.6% |
| Dec 2017 | $157.24M | +58.2% | 92.3% | 32.0% | 5.6% |
| Dec 2016 | $99.38M | N/A | 89.6% | 19.0% | -7.8% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 85.7% from the year before. In the quarter ended Jun 2026, net income fell 33.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $796.85M | $792.32M | $750.26M | $766.55M | $745.42M | $550.70M | $388.22M | $249.52M | $157.24M | $99.38M |
| Cost of revenue | $57.60M | $48.22M | $66.92M | $65.08M | $46.72M | $29.59M | $14.02M | $6.04M | $12.17M | $10.32M |
| Gross profit | $739.26M | $744.11M | $683.34M | $701.48M | $698.71M | $521.11M | $374.21M | $243.49M | $145.07M | $89.06M |
| Research and development | $121.03M | $123.75M | $135.84M | $143.14M | $125.86M | $61.82M | $29.30M | $43.89M | $11.50M | $5.74M |
| Operating income | $87.49M | $65.85M | -$27.01M | $1.74M | $13.41M | -$275.72M | $139.68M | $77.25M | $50.31M | $18.92M |
| Net income | $30.44M | $16.39M | -$8.87M | -$32.83M | -$25.25M | -$293.62M | $75.80M | $43.79M | $8.84M | -$7.77M |
| EBITDA | $175.20M | $135.22M | $80.03M | $59.33M | $51.39M | -$253.92M | $153.66M | $88.29M | $59.41M | $28.01M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $200.41M | $194.01M | $194.78M | $196.03M | $203.07M | $202.97M | $198.58M | $195.25M | $200.61M | $197.88M | $196.64M | $179.96M |
| Gross profit | $179.41M | $173.85M | $177.32M | $182.61M | $189.72M | $189.61M | $186.39M | $183.57M | $188.74M | $185.41M | $181.47M | $161.24M |
| Operating income | $23.63M | $14.01M | $22.68M | $14.62M | $26.81M | $23.38M | $18.18M | $20.41M | $19.88M | $7.38M | -$18.29M | -$38.33M |
| Net income | $8.54M | $1.17M | $5.42M | $1.12M | $12.84M | $11.05M | $6.74M | $3.96M | $6.69M | -$1.01M | -$25.87M | -$38.49M |
Balance Sheet
As of Dec 2025, total debt of $488.26M exceeded cash and equivalents by $226.44M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.40B | $1.39B | $1.59B | $1.60B | $1.61B | $1.47B | $386.80M | $314.79M | $286.87M | $295.65M |
| Current assets | $643.10M | $659.25M | $872.79M | $919.69M | $1.09B | $1.09B | $86.58M | $73.07M | N/A | N/A |
| Cash and equivalents | $261.82M | $448.35M | $672.30M | $757.16M | $941.11M | $968.69M | $26.05M | $34.60M | $17.54M | $23.61M |
| Total liabilities | $787.80M | $663.41M | $826.84M | $789.80M | $775.95M | $758.75M | $737.37M | $1.48B | $136.01M | $46.08M |
| Short-term debt | $5.00M | $5.00M | $8.79M | $7.03M | $7.03M | $7.03M | $7.03M | $5.43M | N/A | N/A |
| Long-term debt | $483.26M | $486.71M | $647.70M | $651.80M | $655.86M | $659.89M | $663.89M | $716.81M | N/A | N/A |
| Shareholder equity | $616.26M | $724.66M | $761.96M | $814.83M | $831.68M | $711.36M | -$1.09B | -$1.16B | -$86.19M | $8.11M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.34B | $2.02B | $1.40B | $1.33B | $1.32B | $1.30B | $1.39B | $1.35B | $1.48B | $1.45B | $1.59B | $1.71B |
| Total liabilities | $1.70B | $1.40B | $787.80M | $724.79M | $675.67M | $640.92M | $663.41M | $658.41M | $805.99M | $822.89M | $826.84M | $826.70M |
| Cash and equivalents | $296.11M | $235.71M | $261.82M | $273.53M | $281.32M | $300.98M | $448.35M | $423.78M | $524.90M | $533.29M | $672.30M | $794.90M |
| Shareholder equity | $647.60M | $621.99M | $616.26M | $600.71M | $643.03M | $654.35M | $724.66M | $696.43M | $669.40M | $631.07M | $761.96M | $881.27M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 55.9% of operating cash flow. Share repurchases came to 230.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $167.90M | $183.89M | $138.29M | $146.78M | $178.78M | $131.34M | $83.29M | $45.25M |
| Capital expenditures | $74.02M | $70.35M | $55.77M | $55.21M | $34.46M | $35.82M | $5.75M | $3.46M |
| Free cash flow | $93.88M | $113.55M | $82.53M | $91.57M | $144.32M | $95.52M | $77.54M | $41.80M |
| Dividends paid | N/A | N/A | $1 | N/A | $22.67M | $78.71M | $0 | $1.35B |
| Share repurchases | $216.37M | $158.84M | $103.97M | $101.72M | $0 | $4.94M | $0 | $0 |
| Investing cash flow | -$119.96M | -$70.35M | -$55.77M | -$210.50M | -$178.73M | -$91.62M | -$37.05M | -$3.46M |
| Financing cash flow | -$234.47M | -$337.50M | -$167.40M | -$120.23M | -$30.53M | $905.82M | -$54.78M | -$24.73M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $80.83M | $11.84M | $32.89M | $76.02M | $49.58M | $9.41M | $44.74M | $86.86M | $9.70M | $42.59M | $15.87M | $60.27M |
| Capital expenditures | $14.41M | $21.64M | $15.83M | $18.00M | $18.32M | $21.88M | $16.64M | $15.86M | $17.23M | $20.61M | $12.87M | $13.65M |
| Free cash flow | $66.42M | -$9.81M | $17.06M | $58.02M | $31.27M | -$12.46M | $28.10M | $71.00M | -$7.53M | $21.97M | $3.00M | $46.62M |
Frequently Asked Questions About GDRX
What is Goodrx Holdings' annual revenue?
Goodrx Holdings reported revenue of $796.85M for the fiscal year ended Dec 31, 2025.
How fast is Goodrx Holdings' revenue growing?
Revenue was up 0.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.3%.
Is Goodrx Holdings profitable?
Yes. Goodrx Holdings reported net income of $30.44M for the fiscal year ended Dec 31, 2025, with a net margin of 3.8%.
How much free cash flow does GDRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $167.90M minus capital expenditures of $74.02M produced free cash flow of $93.88M.
How much debt does Goodrx Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $483.26M, short-term debt of $5.00M and cash and equivalents of $261.82M.
GDRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors